New drug combo tested for Tough-to-Treat pancreatic cancer

NCT ID NCT03854110

First seen Nov 01, 2025 · Last updated Apr 18, 2026 · Updated 30 times

Summary

This early-stage trial is testing the safety and initial effectiveness of a new drug called GP-2250 when given with an existing chemotherapy, gemcitabine. It is for adults with advanced pancreatic cancer that has worsened after prior treatment. The main goal is to find a safe dose and see how well the body handles the combination.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Abramson Cancer Center at the University of Pennsylvania

    Phildelphia, Pennsylvania, 19104, United States

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Hoag Family Cancer Institute

    Newport Beach, California, 92663, United States

  • University of Kansas Cancer Center

    Fairway, Kansas, 66205, United States

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina, 27292, United States

Conditions

Explore the condition pages connected to this study.